Study title:
Lebrethon M-C, Grossman AB, Afshar F, Plowman PN, Besser GM, Savage MO. Linear Growth and Final Height after Treatment for Cushing's Disease in Childhood. Journal of Clinical Endocrinology and Metabolism 2000; 85(9):3262-3265.Lebrethon M-C, Grossman AB, Afshar F, Plowman PN, Besser GM, Savage MO. Linear Growth and Final Height after Treatment for Cushing's Disease in Childhood. Journal of Clinical Endocrinology and Metabolism 2000; 85(9):3262-3265.
Type of medicine: Medicines containing chemical active substances
|
Therapeutic area: Endocrine System Diseases [C19]
|
Brands: Please see report, Please see report |
MAH holders: Please see report, Please see report |
Assessment: |
Active substance: GOSERELIN |
ATC code: |
Document link:
|
Document date:
|
Study number: |
EudraCT number:
|
Scope of study: Clinical |
Population of study subjects:
|
Preterm newborn Infants
|
Newborn infants
(1 to 27 days)
|
Infants and toddlers
(28 days to 24 months)
|
Children
(2 to 11 years)
|
Adolescents
(12 to 18 years)
|
|
-
|
-
|
-
|
-
|
-
|